Seton ends distribution deal with Acme:
This article was originally published in Clinica
For a payment of about $2 million, Seton is to end its five-year distribution arrangement with Acme. The payment will redeem an outstanding loan to Seton and pay for the Acme shares that Seton holds. Seton will replace Acme with Convatec, a company with a status in the US healthcare market which Seton hopes will mean a larger distribution network. Convatec, a subsidiary of Bristol-Myers Squibb, is to pay a total of $2.5 million to complete the deal.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.